文献速递慢性静脉疾病

冲洗式腔内激光消融(fEVLA)治疗下肢静脉功能不全的系统评价与Meta分析

Flush Endovenous Laser Ablation (fEVLA) in the Treatment of Lower Limb Venous Insufficiency a Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2024-12-27

该系统评价与Meta分析纳入11项研究、2738例患者和3147条主干静脉,评估冲洗式腔内激光消融(fEVLA)治疗慢性静脉功能不全的安全性和有效性。汇总静脉内热诱导血栓(EHIT)≥II级发生率为1.37%(95%CI:0.57-3.28),大隐静脉中期闭塞率为97.59%(95%CI:94.89-98.88);与标准EVLA相比,fEVLA在腹股沟区近端复发(RR 0.35,95%CI:0.16-0.80)和残端长度(MD -7.23,95%CI:-11.59至-2.88)方面更优。

要点

  • fEVLA汇总EHIT≥II级发生率为1.37%(95%CI:0.57-3.28),汇总DVT为0.97%(95%CI:0.64-1.47),PE为0.04%。
  • fEVLA组腹股沟区近端复发风险低于sEVLA组(RR 0.35,95%CI:0.16-0.80),残端长度短于sEVLA组(MD -7.23,95%CI:-11.59至-2.88)。
  • GSV闭塞率(OR 3.26,95%CI:0.76-13.97)和新发AASV反流(RR 0.45,95%CI:0.11-1.77)的差异未达统计学显著,趋势 favoring fEVLA 需进一步研究。

核心结论

  • 本综述表明fEVLA具有安全性,并提示fEVLA在腹股沟区近端复发方面可能优于sEVLA。
  • fEVLA在GSV闭塞和新发AASV反流方面的优势趋势值得进一步研究。

研究设计与样本

  • 遵循PRISMA 2020指南的系统评价与Meta分析,检索建库至2024年3月发表的研究。
  • 纳入单臂研究和比较fEVLA与标准EVLA(sEVLA)的研究。
  • 共纳入11项研究,涵盖2738例患者和3147条主干静脉。

主要发现

  • 汇总EHIT≥II级发生率为1.37%(95%CI:0.57-3.28)。
  • Meta回归显示,隐股交界(SFJ)处应用的线性静脉内能量密度(LEED)与EHIT≥II级结局相关(β=0.011,P<0.01)。
  • 汇总GSV中期闭塞率为97.59%(95%CI:94.89-98.88)。
  • 汇总DVT估计值为0.97%(95%CI:0.64-1.47),粗DVT和PE估计值分别为0.97%和0.04%。
  • GSV闭塞(OR 3.26,95%CI:0.76-13.97)和新发AASV反流(RR 0.45,95%CI:0.11-1.77)的比较分析显示非统计学显著趋势 favoring fEVLA;EHIT≥II级在两种技术间差异无统计学意义(RR 1.00,95%CI:0.18-5.53);腹股沟区近端复发(RR 0.35,95%CI:0.16-0.80)和残端长度(MD -7.23,95%CI:-11.59至-2.88)方面fEVLA具有统计学显著优势。

临床怎么用

  • 原文结论提示fEVLA具有安全性,并可能改善腹股沟区近端复发,但GSV闭塞和新发AASV反流的优势趋势需进一步研究。

局限性

  • 原文结论指出,fEVLA在GSV闭塞和新发AASV反流方面的优势趋势需进一步研究(merits further research)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency (CVI). METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA). The primary endpoint was endovenous heat-induced thrombosis (EHIT) class ≥ II. RESULTS: Eleven studies encompassing 2738 patients and 3147 truncal veins were included. The pooled EHIT ≥ II was 1.37% (95% CI: 0.57-3.28). Meta-regression identified an association between linear endovenous energy density (LEED) applied at the saphenofemoral junction (SFJ) and EHIT ≥ II outcomes (β = 0.011, P < 0.01). The pooled medium-term great saphenous vein (GSV) occlusion was 97.59% (95% CI: 94.89-98.88). The pooled and crude deep vein thrombosis (DVT) and pulmonary embolism (PE) estimates were 0.97% (95% CI: 0.64-1.47) and 0.04%. The comparative analysis regarding GSV occlusion, odds ratio (OR) 3.26 (95% CI: 0.76-13.97) and refluxing anterior accessory saphenous vein (AASV), risk ratio (RR) 0.45 (95% CI: 0.11-1.77) suggested a nonstatistically significant trend favoring fEVLA. Nonstatistically significant differences were identified in terms of EHIT ≥ II between the techniques, RR 1.00(95% CI: 0.18-5.53). Statistically significant differences favoring fEVLA were identified in terms of proximal groin recurrence RR 0.35 (95% CI: 0.16-0.80) and stump length (mean difference) MD -7.23 (95% CI: -11.59to-2.88). CONCLUSION: This review has demonstrated the safety of fEVLA while also suggesting a potentially improved efficacy of fEVLA over sEVLA in terms of proximal groin recurrence. Moreover, the trend indicating fEVLA's superiority in terms of GSV occlusion and the occurrence of new-onset AASV reflux merits further research.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bontinis V, Bontinis A, Giannopoulos A, et al. Flush Endovenous Laser Ablation (fEVLA) in the Treatment of Lower Limb Venous Insufficiency a Systematic Review and Meta-Analysis. Ann Vasc Surg. 2024. PMID: 39734000. doi:10.1016/j.avsg.2024.12.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。